Abstract:Objective: Hemangiomas are the most common benign vascular tumors of infancy. Although most infantile hemangiomas (IHs) have the ability to involute spontaneously after initial proliferation and resolve without consequence, intervention is required in a subset of IHs, which develop complications resulting in ulceration, bleeding, or aesthetic deformity. The primary treatment for this subset of IHs is pharmacological intervention, and propranolol has become the new first-line treatment for complicated hemangiomas. Here, we evaluated the efficacy of propranolol on proliferation IH in a clinical cohort including 578 patients.Methods: We retrospectively reviewed a total of 578 IH patients who were treated with oral propranolol from January 2010 to December 2012. Responses to the propranolol treatment were graded as: excellent, good, poor, or no response. Based on the response to propranolol treatment (once daily at a dose of 1.0 mg/kg for patients younger than 2 months; twice daily at daily total dose of 2 mg/kg for patients older than 2 months), additional pharmacotherapies or surgery were used for IH patients for satisfactory clinical outcome.Results: Five hundred and sixty (96.9%) of 578 IH patients in our study responded to oral propranolol treatment, and the response rate was significantly different for different ages of patients (P<0.05), with the youngest patients having the highest response rate. The mean time of treatment was 6 months (range, 3-12 months). For example, response rate to propranolol was 98.1% in patients younger than 2 months, compared with 93.3% in patients older than 2 months and younger than 8 months, and 73.7% in patients older than 8 months. One hundred and thirty one patients who exhibited incompletely involuted hemangiomas were further treated with timolol maleate (n=89) or pulsed dye laser (n=42). One hundred and seventeen (89.3%) of 131 patients showed a positive response. There were no instances of life-threatening complications after propranolol. However, minor side effects were observed including 10 (1.73%) cases of sleep disturbance, 7 (1.21%) cases of diarrhea, and 5 (0.86%) cases of bronchospasm.Conclusion: IH requires early intervention. During the involution phase, tapering propranolol dosage can be done to minimize side effects before discontinuing treatment. For patients exhibiting telangiectasia and chromatosis after propranolol treatment, administration of a 0.5% solution of timolol maleate or pulse dye laser is an effective therapeutic approach for complete involution.

Adverse effects of propranolol treatment for infantile hemangiomas in China

Efficacy and adverse effects of oral propranolol in infantile hemangioma: a meta-analysis of comparative studies

Safety assessment of propranolol for infantile hemangioma: a study in an Asian population

Safety of oral propranolol for neonates with problematic infantile hemangioma: a retrospective study in an Asian population

Preliminary Experience on Treatment of Infantile Hemangioma with Low-Dose Propranolol in China

Treatment of infantile hemangiomas with low-dose propranolol: evaluation of short-term efficacy and safety]

A Survey on Clinical Use of Propranolol for Infantile Hemangiomas in Mainland China.

Is Propranolol Safe and Effective for Outpatient Use for Infantile Hemangioma? A Prospective Study of 679 Cases From One Center in China.

Safety and Tolerance of Propranolol in Neonates with Severe Infantile Hemangiomas: a Prospective Study

Propranolol for problematic head and neck hemangiomas: an analysis of 37 consecutive patients.

Propranolol in the treatment of problematic infantile hemangiomas

Clinical Observations on Infantile Hemangiomas Treated with Low-Dose Propranolol

Effects of Systemic Propranolol Treatment on Physical Growth of Patients with Infantile Hemangiomas

[A Prospective Study of Propranolol As First-Line Treatment for Problematic Infantile Hemangioma in China].

Effectiveness And Safety Of Oral Propranolol Versus Other Treatments For Infantile Hemangiomas: A Meta-Analysis

Timing and Safety of Oral Propranolol for Infantile Hemangioma

The efficacy of oral propranolol for infantile hemangiomas in 68 cases

Propranolol Therapy for Infantile Hemangioma: Our Experience

Propranolol Versus Atenolol in the Treatment of Infantile Hemangioma：a Comparative Study

Clinical observation of treating infantile head and neck hemangioma with oral propranolol

Intolerable Side Effects During Propranolol Therapy for Infantile Hemangioma: Frequency, Risk Factors and Management